Home > Healthcare > Biotechnology > Biotechnology R&D > Non-animal Alternative Testing Market

Non-animal Alternative Testing Market Analysis

  • Report ID: GMI5704
  • Published Date: May 2023
  • Report Format: PDF

Non-animal Alternative Testing Market Analysis

 Non-animal Alternative Testing Market, By Product Type)

To understand key trends  
Download Free Sample
 

Based on product type, the non-animal alternative testing market is segmented into organs-on-chips, cell lines, and tissue lines. The organ-on-chips segment dominated in 2022 with a market size of USD 872.9 million. The advantages of organ-on-chips (OOCs) over cell culture, animal models, and human clinical trials have attracted the interest of both the medical and pharmaceutical communities, that are working on producing personalised medicines.
 

For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) established a novel concept for Organs-on-a-Chip to investigate treatments for inflammatory diseases and ailments. Organs-on-a-chip are made up of millions of cells arranged on a platform to mimic the functioning of various organs and can be used as a tool for assessing and developing new treatments for complicated diseases without the usage of animals. Such benefits offered by OOCs is expected to propel the segmental growth.
 

 Global Non-animal Alternative Testing Market Share, By Method,

To understand key market trends  
Download Free Sample
 

Based on technology, the non-animal alternative testing market is segmented into cell culture technology, high throughput technology, molecular imaging, and omics technology. The cell culture technology segment accounted for USD 746.9 million in 2022. The increase is due to the fact that researchers frequently utilise cell culture technologies for analysing a large number of test results at once. Also, numerous pharmacological experiments are performed on eukaryotic cells, preferably human cells, that have been cultured under strictly monitored in vitro conditions to mimic the external environment of the human body.

 

Based on application, the non-animal alternative testing market is segmented into infectious diseases, immunological diseases, oncology, cardiovascular diseases, diabetes, genetic diseases, and neurological diseases. The infectious diseases segment dominated the market in 2022, with a CAGR of 7.8%. The dominance of segment is due to the fact that scientists estimate that more than 6 out of every 10 known infectious diseases in people can be spread from animals, and 3 out of every 4 new or emerging infectious diseases in people come from animals. Hence, the utilization of non-animal alternative testing for infectious diseases will accelerate the market growth.
 

Based on end-user, the non-animal alternative testing market is segmented into pharmaceutical companies, biotechnological companies, the cosmetics industry, research institutes & academics, contract research organization (CROs) and other end-users. The pharmaceutical industry segment is expected show 11% CAGR during the analysis period. The expansion is due to the pharmaceutical sector boosting its research and development efforts to provide new treatments for a variety of conditions. Also, rising disapproval to using animals for drug testing is further inspiring corporations to use in silico drug testing procedures to avoid any type of ethics concern. As a result, the market for non-animal alternative testing is predicted to increase at an exponential rate in the forecast period.
 

North America Non-animal Alternative Testing Market,

To understand regional trends  Download Free Sample
 

North America non-animal alternative testing market surpassed USD 653.8 million in 2022 with a growth rate of 8.2%. The region is dominating due to the presence of key players in these regions along with rising government support for non-animal alternative testing. Also, increasing prevalence of chronic diseases along with investment by key players in R&D activities to develop novel product is expected to supplement the market landscape.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for non-animal alternative testing was valued at USD 1,725.0 million in 2022 and is expected to surpass USD 4,534.2 million by 2032 at 10.3% CAGR attributed to the rising emphasis on animal welfare.

The cell culture technology segment generated USD 746.9 million in 2022 and is anticipated to grow at a steady pace through 2032 owing to its extensive use by researchers for analyzing many test results simultaneously.

The North America non-animal alternative testing market amassed USD 653.8 million in 2022 and is poised to grow at 8.2% CAGR through 2032 due to the presence of key players in the region.

AlveoliX AG, MIMETAS, MatTek Corporation, Emulate, Inc, VITROCELL Systems GmbH, Bio-Rad Laboratories, Inc., Hurel Corporation, Evotec SE, MB Research Laboratories, and TissUse GmbH are the prominent companies in the market.

Non-animal Alternative Testing Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 342
  • Countries covered: 20
  • Pages: 180
 Download Free Sample